公开(公告)号：US11555007B2

公开(公告)日：2023-01-17

申请号：US17073386

申请日：2020-10-18

Applicant: Cellix Bio Private Limited

Inventor： Mahesh Kandula

IPC: C07C225/28 ,  C07C69/604

Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases.

公开(公告)号：US20200308488A1

公开(公告)日：2020-10-01

申请号：US16754409

申请日：2018-11-01

Applicant: DIC Corporation

Inventor： Kenta Shimizu ,  Masanao Hayashi ,  Yutaka Kadomoto ,  Tetsuo Kusumoto ,  Ayaki Hosono ,  Shinya Yamamoto ,  Masanori Miyamoto ,  Hidetomo Kai

IPC: C09K19/46 ,  C07C69/604 ,  C07D319/06 ,  G02F1/1337

Abstract: The compound is represented by general formula (i). In the compound, in a group Ki1, at least two secondary carbon atoms in an alkyl group (a linear alkyl, halogenated alkyl, or cyanogenated alkyl group having 3 to 40 carbon atoms) are replaced with —C(═Xi1)— and/or —CH(—CN)—, where Xi1 is an oxygen atom, a sulfur atom, NH, or NR13; in addition, a group Ai2, a group Ai3, or the group Ki1 includes, as a substituent, at least one Pi1-Spi1- group, where Pi1 is a polymerizable group, and SPi1 is a spacer group or a single bond. The liquid crystal composition including the compound represented by general formula (i) can be adsorbed onto substrates between which a liquid crystal layer is held, and, consequently, without the use of an alignment film, liquid crystal molecules can be maintained in a state in which the liquid crystal molecules are aligned in a vertical direction.

公开(公告)号：US10774059B2

公开(公告)日：2020-09-15

申请号：US16446604

申请日：2019-06-19

Applicant: Cellix Bio Private Limited

Inventor： Mahesh Kandula

IPC: C07C69/604 ,  C07C69/616 ,  A61K8/37 ,  C07D317/12 ,  A61P29/00

Abstract: The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications.

公开(公告)号：US20180244602A9

公开(公告)日：2018-08-30

申请号：US15249061

申请日：2016-08-26

Applicant: Massachusetts Institute of Technology

Inventor： Timothy M. Swager ,  Yanchuan Zhao ,  Silvia Veleirinho de Oliveira Rocha

IPC: C07C69/604 ,  C07C67/293 ,  B01D53/02 ,  B01J20/26

CPC classification number: C07C69/604 ,  B01D53/02 ,  B01D2253/20 ,  B01D2257/40 ,  B01D2257/7027 ,  B01D2257/704 ,  B01J20/261 ,  C07C67/293

Abstract: Methods for mechanochemically synthesizing compositions comprising bridged bicyclic-based compounds such as iptycene-based compounds are generally provided. In some cases, two or more polycyclic aromatic hydrocarbons may be mechanochemically reacted such that the product comprises the bridged bicyclic-based compound. In some embodiments, the product (e.g., the bridged bicyclic compound) may comprise two or more [2.2.2] bicyclic cores. In certain embodiments, the mechanochemical reactions described herein may produce higher order bridged bicyclic-based compounds such as oligoiptcyenes or poly-iptycenes. In certain embodiments, the bridged bicyclic based compound comprises a molecular cage.

公开(公告)号：US20180210114A1

公开(公告)日：2018-07-26

申请号：US15497211

申请日：2017-04-26

Applicant: HON HAI PRECISION INDUSTRY CO., LTD.

Inventor： HSIU-WEN CHIEN

IPC: G02B1/04 ,  C08G77/04 ,  C07F9/53 ,  C07F7/08 ,  C07D303/16 ,  C07D207/267 ,  C07C245/22 ,  C07C233/09 ,  C07C69/604 ,  C07C69/602 ,  C07C69/54 ,  C07C49/84 ,  C07C49/83 ,  C07C49/82 ,  C07C43/16

CPC classification number: G02B1/043 ,  C07D207/267 ,  C07D303/16 ,  C07F7/0838 ,  C07F7/1804 ,  C07F9/5337 ,  C08G77/04 ,  C08L83/04

Abstract: A wetness-retaining ophthalmic lens material comprises an organic monomer, a cross-linking agent, an initiator, a salt, and a solvent. The salt dissolves in the water dissociates a plurality of anions and cations, which bind to water molecules and retard the evaporation of the water molecules, the ophthalmic lens material thus can keep wet for a long time. An ophthalmic lens made of the ophthalmic lens material is also provided.

公开(公告)号：US09969674B2

公开(公告)日：2018-05-15

申请号：US15303939

申请日：2015-04-16

Applicant: RATIOPHARM GMBH

Inventor： Wolfgang Albrecht ,  Roland Selig ,  Frank Lehmann ,  Richard Guserle ,  Annemarie Maier

IPC: C07C69/60 ,  C07C69/604 ,  A61K31/194 ,  A61K31/22

CPC classification number: C07C69/604 ,  C07C69/60

Abstract: The present invention relates to novel compounds, e.g. for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis, rheumatoid arthritis and psoriasis.

公开(公告)号：US20180057443A1

公开(公告)日：2018-03-01

申请号：US15249061

申请日：2016-08-26

Applicant: Massachusetts Institute of Technology

Inventor： Timothy M. Swager ,  Yanchuan Zhao ,  Silvia Veleirinho de Oliveira Rocha

IPC: C07C69/604 ,  C07C67/293 ,  B01D53/02 ,  B01J20/26

CPC classification number: C07C69/604 ,  B01D53/02 ,  B01D2253/20 ,  B01D2257/40 ,  B01D2257/7027 ,  B01D2257/704 ,  B01J20/261 ,  C07C67/293

Abstract: Methods for mechanochemically synthesizing compositions comprising bridged bicyclic-based compounds such as iptycene-based compounds are generally provided. In some cases, two or more polycyclic aromatic hydrocarbons may be mechanochemically reacted such that the product comprises the bridged bicyclic-based compound. In some embodiments, the product (e.g., the bridged bicyclic compound) may comprise two or more [2.2.2] bicyclic cores. In certain embodiments, the mechanochemical reactions described herein may produce higher order bridged bicyclic-based compounds such as oligoiptcyenes or poly-iptycenes. In certain embodiments, the bridged bicyclic based compound comprises a molecular cage.

公开(公告)号：US09868690B2

公开(公告)日：2018-01-16

申请号：US14647677

申请日：2013-12-20

Applicant: RATIOPHARM GMBH

Inventor： Wolfgang Albrecht ,  Roland Selig ,  Sebastian Rabe ,  Richard Guserle ,  Annemarie Maier

IPC: C07C225/22 ,  A61K31/495 ,  A61K31/54 ,  C07C69/604 ,  C07C219/08 ,  C07D295/088 ,  C07D317/40 ,  C07F9/09

CPC classification number: C07C225/22 ,  A61K31/225 ,  A61K31/495 ,  A61K31/54 ,  C07C69/604 ,  C07C219/08 ,  C07D295/088 ,  C07D317/40 ,  C07F9/091

Abstract: The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis.

公开(公告)号：US09782335B2

公开(公告)日：2017-10-10

申请号：US15133552

申请日：2016-04-20

Applicant: ELC Management LLC

Inventor： Daniel H. Maes ,  Fatemeh Mohammadi ,  Lisa Qu ,  Anna Czarnota ,  Thomas Mammone ,  Julius R. Zecchino ,  Lieve Declercq

IPC: A61K31/216 ,  A61K8/37 ,  A61K8/34 ,  A61K8/42 ,  A61K8/58 ,  A61K8/60 ,  A61K31/05 ,  A61Q19/00 ,  A61Q1/10 ,  A61Q1/12 ,  A61Q19/08 ,  A61Q1/02 ,  A61Q1/06 ,  A61Q1/08 ,  A61Q17/04 ,  A61K8/97 ,  C07C69/604 ,  A61K8/02 ,  A61K8/06 ,  A61K8/25 ,  C07C69/94 ,  A61K8/891 ,  C07C69/017 ,  C07C69/30

CPC classification number: A61K8/375 ,  A61K8/0241 ,  A61K8/062 ,  A61K8/064 ,  A61K8/066 ,  A61K8/25 ,  A61K8/347 ,  A61K8/37 ,  A61K8/42 ,  A61K8/585 ,  A61K8/60 ,  A61K8/602 ,  A61K8/891 ,  A61K8/97 ,  A61K31/05 ,  A61K2800/31 ,  A61K2800/43 ,  A61K2800/54 ,  A61K2800/591 ,  A61K2800/596 ,  A61Q1/02 ,  A61Q1/06 ,  A61Q1/08 ,  A61Q1/10 ,  A61Q1/12 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/007 ,  A61Q19/08 ,  C07C69/017 ,  C07C69/30 ,  C07C69/604 ,  C07C69/94

Abstract: Succinic acid esters of resveratrol and topical compositions containing the esters.

公开(公告)号：US09422226B2

公开(公告)日：2016-08-23

申请号：US14124562

申请日：2012-06-08

Applicant: John Guzowski ,  William Kiesman ,  Erwin Irdham

Inventor： John Guzowski ,  William Kiesman ,  Erwin Irdham

IPC: C07C67/297 ,  C07C67/52 ,  C07C67/08 ,  C07C69/60 ,  C07C69/604

CPC classification number: C07C67/52 ,  C07B2200/13 ,  C07C67/08 ,  C07C67/297 ,  C07C69/60 ,  C07C69/604

Abstract: The present invention describes a process for the preparation of dimethyl fumarate. The process involves the esterification of fumaric acid and methanol in the presence of sulfuric acid as an acid catalyst. The high purity dimethyl fumarate contains no more than trace amounts of dimethyl sulfate. The present invention also provides a process for the preparation of highly pure dimethyl fumarate with a particle size from 20 to 250μπι.

Abstract translation: 本发明描述了制备富马酸二甲酯的方法。 该方法包括在作为酸催化剂的硫酸存在下富马酸和甲醇的酯化。 高纯度富马酸二甲酯含有不超过痕量的硫酸二甲酯。 本发明还提供了制备粒径为20-250μm的高纯度富马酸二甲酯的方法。